Pierre Fabre, Partner Of The Toulouse Onco Week
* The Toulouse Onco Week will take place from February 3rd to 5th alongside the World Cancer Day; it will gather numerous international scientists and showcase the latest innovations in oncology
* Involved in the fight against cancer for over 30 years and historic ambassador of the Toulouse Oncopole, Pierre Fabre laboratories will attend and support this first edition of the Toulouse Onco Week
* Pierre Fabre R&D team will be presenting 10 abstracts
Castres (France), January 28, 2016. Pierre Fabre laboratories, 2nd largest French independent phamaceutical group, announce their participation to the 1st edition of the Toulouse Onco Week which will take place from February 3rd to 5th at the Pierre Baudis Congress Center in Toulouse under the High Patronage of Mr. François Hollande, President of the Republic of France.
The Toulouse Onco Week is organized by the Cancer Research Center of Toulouse (CRCT) in partnership with Cancer-Bio-Health Competitiveness Cluster, the French Institute of Health and Medical Research (Inserm), the Toulouse Cancer Santé foundation, Toulouse Métropole and the agency So Toulouse. In addition to their institutional support, Pierre Fabre laboratories will share their research results in oncology via the presentation of 10 abstracts. Pierre Fabre R&D oncology and onco-dermatology team will welcome attendees at the company's booth and Laurent Audoly, Head of R&D for Pierre Fabre Pharmaceutical Division, will present Pierre Fabre laboratories on February, 3rd.
The group's participation and support to this event demonstrate its strong commitment to the Toulouse region and its Cancer Research Center's development, the Oncopole, as a global center of excellence in oncology. Pierre Fabre, which R&D Center is located on the Oncopole Campus and gathers over 500 employees, is one of the Oncopole's historic ambassador and major private stakeholder. Unique in Europe, the Oncopole is a campus gathering on the same site public and private actors in research, training, patient, business, technology platforms, clinical trials to fight against cancer. « The Toulouse Onco Week is a new opportunity for Pierre Fabre laboratories to present their expertise and research projects in oncology and to share experience with the numerous scientists and international innovators that will attend the event in Toulouse. It is therefore an event that falls within the framework of our Open Innovation strategy and that highlights our unfailing support to the Toulouse region which is worldwide known for its oncology research," comments Bertrand Parmentier, general manager of Pierre Fabre laboratories.
About the Toulouse Onco Week
The Toulouse Onco Week (TOW) aims to unite all forces in the fight against cancer: scientists, clinicians, caregivers, industry, pharmaceutical and biotechnology companies, public authorities and charities. The event will be part of World Cancer Day 2016 on February 4th. This initiative was founded by the Toulouse Center for Cancerology Research (CRCT)* and will be conducted in partnership with the Cancer-Bio-Health cluster, the Toulouse Cancer Health Foundation, Toulouse Métropole and So Toulouse.
More information: www.toulouse-onco-week.org
About Pierre Fabre
Pierre Fabre is a French privately-owned health and beauty care company created in 1961 by Mr. Pierre Fabre. In 2014, global sales reached over €2.2 billion* across 130 countries. The company is structured around two divisions: Pharmaceuticals (Prescription drugs, Consumer Health Care) and Dermo-cosmetics (including the European and Asian market-leader Eau Thermale Avène brand). Pierre Fabre employs some 11,000 people worldwide and owns subsidiary in 43 countries. In 2014, the company allocated 17 percent of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care.
Pierre Fabre's oncology know-how is based on 3 decades of experience in the discovery, development and global commercialization of innovative cancer drugs including monoclonal antibodies and natural cytotoxic agents. The company performs its oncology R&D in two major research centres: the Pierre Fabre Immunology Centre (CIPF) based in Saint-Julien-en-Genevois (France) and the Pierre Fabre Research Institute (IRPF) located on the Toulouse-Oncopole campus. The latter is officially recognized by the French government as a National Center of Excellence for cancer research.
Through the controlled company Pierre Fabre Participations, Pierre Fabre Laboratories are 86% owned by the Pierre Fabre Foundation, a recognized public-interest organization since 1999. Up to 7.8% of the remaining shares are held by the company's employees and are self-monitored.
For more information on Pierre Fabre, please go to www.pierre-fabre.com.
* Involved in the fight against cancer for over 30 years and historic ambassador of the Toulouse Oncopole, Pierre Fabre laboratories will attend and support this first edition of the Toulouse Onco Week
* Pierre Fabre R&D team will be presenting 10 abstracts
Castres (France), January 28, 2016. Pierre Fabre laboratories, 2nd largest French independent phamaceutical group, announce their participation to the 1st edition of the Toulouse Onco Week which will take place from February 3rd to 5th at the Pierre Baudis Congress Center in Toulouse under the High Patronage of Mr. François Hollande, President of the Republic of France.
The Toulouse Onco Week is organized by the Cancer Research Center of Toulouse (CRCT) in partnership with Cancer-Bio-Health Competitiveness Cluster, the French Institute of Health and Medical Research (Inserm), the Toulouse Cancer Santé foundation, Toulouse Métropole and the agency So Toulouse. In addition to their institutional support, Pierre Fabre laboratories will share their research results in oncology via the presentation of 10 abstracts. Pierre Fabre R&D oncology and onco-dermatology team will welcome attendees at the company's booth and Laurent Audoly, Head of R&D for Pierre Fabre Pharmaceutical Division, will present Pierre Fabre laboratories on February, 3rd.
The group's participation and support to this event demonstrate its strong commitment to the Toulouse region and its Cancer Research Center's development, the Oncopole, as a global center of excellence in oncology. Pierre Fabre, which R&D Center is located on the Oncopole Campus and gathers over 500 employees, is one of the Oncopole's historic ambassador and major private stakeholder. Unique in Europe, the Oncopole is a campus gathering on the same site public and private actors in research, training, patient, business, technology platforms, clinical trials to fight against cancer. « The Toulouse Onco Week is a new opportunity for Pierre Fabre laboratories to present their expertise and research projects in oncology and to share experience with the numerous scientists and international innovators that will attend the event in Toulouse. It is therefore an event that falls within the framework of our Open Innovation strategy and that highlights our unfailing support to the Toulouse region which is worldwide known for its oncology research," comments Bertrand Parmentier, general manager of Pierre Fabre laboratories.
About the Toulouse Onco Week
The Toulouse Onco Week (TOW) aims to unite all forces in the fight against cancer: scientists, clinicians, caregivers, industry, pharmaceutical and biotechnology companies, public authorities and charities. The event will be part of World Cancer Day 2016 on February 4th. This initiative was founded by the Toulouse Center for Cancerology Research (CRCT)* and will be conducted in partnership with the Cancer-Bio-Health cluster, the Toulouse Cancer Health Foundation, Toulouse Métropole and So Toulouse.
More information: www.toulouse-onco-week.org
About Pierre Fabre
Pierre Fabre is a French privately-owned health and beauty care company created in 1961 by Mr. Pierre Fabre. In 2014, global sales reached over €2.2 billion* across 130 countries. The company is structured around two divisions: Pharmaceuticals (Prescription drugs, Consumer Health Care) and Dermo-cosmetics (including the European and Asian market-leader Eau Thermale Avène brand). Pierre Fabre employs some 11,000 people worldwide and owns subsidiary in 43 countries. In 2014, the company allocated 17 percent of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care.
Pierre Fabre's oncology know-how is based on 3 decades of experience in the discovery, development and global commercialization of innovative cancer drugs including monoclonal antibodies and natural cytotoxic agents. The company performs its oncology R&D in two major research centres: the Pierre Fabre Immunology Centre (CIPF) based in Saint-Julien-en-Genevois (France) and the Pierre Fabre Research Institute (IRPF) located on the Toulouse-Oncopole campus. The latter is officially recognized by the French government as a National Center of Excellence for cancer research.
Through the controlled company Pierre Fabre Participations, Pierre Fabre Laboratories are 86% owned by the Pierre Fabre Foundation, a recognized public-interest organization since 1999. Up to 7.8% of the remaining shares are held by the company's employees and are self-monitored.
For more information on Pierre Fabre, please go to www.pierre-fabre.com.